According to the findings of a multicenter phase II clinical trial, treating people who have differentiated thyroid cancer (DTC), an advanced form of thyroid cancer that arises from thyroid follicular cells, with the targeted tyrosine kinase inhibitor (TKI) cediranib in addition to their tre
According to the findings of a multicenter phase II clinical trial, treating patients with differentiated thyroid cancer (DTC), an advanced form of thyroid cancer that arises from thyroid follicular cells, in addition to their treatment with the targeted tyrosine kinase inhibitor (TKI) cedir
According to the findings of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Centre, adding an immunomodulatory agent to treatment with the targeted tyrosine kinase inhibitor (TKI) cediranib did not improve outcomes in patients with differ